Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

16.27 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11
Open 16.27
Bid (Size) 15.00 (100)
Ask (Size) 17.00 (100)
Prev. Close 16.27
Today's Range 16.27 - 16.27
52wk Range 10.99 - 18.91
Shares Outstanding 353,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Second R&D “Teach-in” Webinar
From Bausch + Lomb Corporation
Via Business Wire

Performance

YTD
-1.9%
-1.9%
1 Month
-2.6%
-2.6%
3 Month
-2.7%
-2.7%
6 Month
+3.7%
+3.7%
1 Year
+40.9%
+40.9%

More News

Read More
News headline image
Bausch + Lomb (BLCO) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Corp (NYSE:BLCO) Beats Q1 Estimates, Raises Full-Year Guidance ↗
Via Chartmill
News headline image
Bausch + Lomb (NYSE:BLCO) Posts Better-Than-Expected Sales In Q1 CY2026
Via StockStory
News headline image
Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb (BLCO) Q1 Earnings Report Preview: What To Look For
Via StockStory
News headline image
Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Releases 2025 Sustainability Impact Report
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch Lomb BLCO Q2 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Bausch + Lomb (BLCO) Q3 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Bausch + Lomb (BLCO) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
Topics Initial Public Offering
News headline image
Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program
From Bausch + Lomb Corporation
Via Business Wire
News headline image
3 Cash-Burning Stocks We Keep Off Our Radar
Via StockStory
Topics Bankruptcy
News headline image
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update
From Bausch + Lomb Corporation
Via Business Wire
News headline image
1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off
Via StockStory
News headline image
Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Q4 Rundown: Bausch + Lomb (NYSE:BLCO) Vs Other Medical Devices & Supplies - Specialty Stocks
Via StockStory
News headline image
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29
From Bausch + Lomb Corporation
Via Business Wire
News headline image
3 Reasons BLCO is Risky and 1 Stock to Buy Instead
Via StockStory
Topics Bankruptcy
News headline image
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Billboard Giant Posts $1.6 Billion Revenue as $20.5 Million Bet Makes It a Top Portfolio Holding ↗
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Bausch + Lomb Corporation Common Shares publicly traded?
Yes, Bausch + Lomb Corporation Common Shares is publicly traded.
What exchange does Bausch + Lomb Corporation Common Shares trade on?
Bausch + Lomb Corporation Common Shares trades on the New York Stock Exchange
What is the ticker symbol for Bausch + Lomb Corporation Common Shares?
The ticker symbol for Bausch + Lomb Corporation Common Shares is BLCO on the New York Stock Exchange
What is the current price of Bausch + Lomb Corporation Common Shares?
The current price of Bausch + Lomb Corporation Common Shares is 16.27
When was Bausch + Lomb Corporation Common Shares last traded?
The last trade of Bausch + Lomb Corporation Common Shares was at 05/14/26 07:00 PM ET
What is the market capitalization of Bausch + Lomb Corporation Common Shares?
The market capitalization of Bausch + Lomb Corporation Common Shares is 5.76B
How many shares of Bausch + Lomb Corporation Common Shares are outstanding?
Bausch + Lomb Corporation Common Shares has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.